Targeted therapies have emerged as a cornerstone of precision oncology in PCa, marked by significant advancements in modulating the AR signaling axis, PI3K/AKT/mTOR pathway, DNA damage repair machinery, and PSMA-directed theranostics. The gene discussed is MTOR; the disease is posterior cortical atrophy.